Cystic fibrosis study targets hidden bacterial threat

NCT ID NCT06371261

Ongoing Knowledge-focused Sponsor: Centre Hospitalier Universitaire de la Réunion Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how different types of Achromobacter bacteria affect the lungs of people with cystic fibrosis on Réunion Island. Researchers will analyze sputum samples from 17 patients to see if certain species cause more lung infections or lead to worse outcomes. The goal is to better understand which bacteria are most harmful, so doctors can improve treatment and prevent the spread of dangerous strains.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify which Achromobacter species are most dangerous, leading to better infection control and treatment strategies for cystic fibrosis patients.
What could go wrong: This is a small, observational study with only 17 participants, so findings may not apply to all patients. It does not test a new treatment, so direct patient benefit is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

CHU la Réunion North

Saint-Denis, Reunion
CHU la Réunion South

Saint-Pierre, Reunion

More trials for these conditions

Other studies related to the condition(s) this trial covers.